| Entry |
|
|---|
| Name |
Niraparib tosilate hydrate (JAN);
Niraparib tosylate monohydrate;
Zejula (TN) |
|---|
| Product |
|
|---|
| Formula |
C19H20N4O. C7H8O3S. H2O
|
|---|
| Exact mass |
510.1937
|
|---|
| Mol weight |
510.6052
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG02942 PARP inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG03120): | D11895<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, PARP inhibitor |
|---|
| Disease |
Ovarian cancer [DS: H00027] Fallopian tube cancer [DS: H01554] Primary peritoneal cancer [DS: H01665] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK02 Niraparib
D11895 Niraparib tosilate hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Niraparib
D11895 Niraparib tosilate hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11895 Niraparib tosilate hydrate (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Pentosyltransferases
PARP1
D11895 Niraparib tosilate hydrate (JAN) <JP/US>
PARP2
D11895 Niraparib tosilate hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11895
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11895
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11895
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11895
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 36
1 C8x C 12.1564 -16.5579
2 C8x C 12.1564 -17.9552
3 C8x C 13.3441 -18.6539
4 C8y C 14.6016 -17.9552
5 C8y C 14.6016 -16.5579
6 C8y C 13.3441 -15.8593
7 C8x C 15.9290 -18.3744
8 N4y N 16.7674 -17.2566
9 N5x N 15.9290 -16.1388
10 C5a C 13.3441 -14.4620
11 O5a O 12.1564 -13.7634
12 N1a N 14.6016 -13.7634
13 C8y C 18.0948 -17.2566
14 C8x C 18.7935 -18.5141
15 C8x C 20.1907 -18.5141
16 C8y C 20.8894 -17.2566
17 C8x C 20.1907 -16.0689
18 C8x C 18.7935 -16.0689
19 C1y C 22.2867 -17.2566
20 C1x C 22.9853 -18.5141
21 N1x N 24.3826 -18.5141
22 C1x C 25.0812 -17.2566
23 C1x C 24.3826 -16.0689
24 C1x C 22.9853 -16.0689
25 C8x C 26.7400 -16.5900
26 C8x C 26.7400 -17.9900
27 C8y C 27.9524 -18.6900
28 C8x C 29.1649 -17.9900
29 C8x C 29.1649 -16.5900
30 C8y C 27.9524 -15.8900
31 C1a C 27.9524 -20.0898
32 S4a S 27.9524 -14.4902
33 O1d O 26.5524 -14.4902
34 O1d O 29.3524 -14.4902
35 O1d O 27.9524 -13.0902
36 O0 O 31.7800 -17.2200
BOND 38
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 2
8 7 8 1
9 8 9 1
10 5 9 2
11 6 10 1
12 10 11 2
13 10 12 1
14 8 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 13 18 1
21 19 16 1 #Down
22 19 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 23 24 1
27 19 24 1
28 25 26 2
29 26 27 1
30 27 28 2
31 28 29 1
32 29 30 2
33 25 30 1
34 27 31 1
35 30 32 1
36 32 33 2
37 32 34 2
38 32 35 1
|
|---|
